Merus BV (MRUS) Stock Analysis

Merus BV (MRUS) is a publicly traded company in the HEALTHCARE sector. It trades at $90.00. This page summarizes the public market data, fundamentals, and frequently asked questions for MRUS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $90.00

About Merus BV

Merus NV is a clinical-stage biotechnology company based in Utrecht, Netherlands, focused on the development of bispecific antibody therapies designed to combat cancer. Leveraging its proprietary technology platform, the company creates targeted therapies that aim to enhance immune responses against tumors, fulfilling critical unmet needs in immuno-oncology. With a strong pipeline of innovative clinical candidates, Merus is well-positioned to contribute significantly to the advancing field of...

GNG Research Analysis

GNG Research scores Merus BV (MRUS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for MRUS.

Frequently Asked Questions

Does MRUS pay dividends?

Merus BV (MRUS) does not currently pay a regular dividend.